The Great Peptide Cash Grab Has Begun

Key Points:

• The FDA is set to discuss reclassifying certain peptides on July 23-24, potentially allowing pharmacies to legally compound custom peptide mixes, reversing a 2023 Biden administration restriction.
• Despite career scientists advising against reclassification, industry insiders expect approval due to the committee's composition, prompting telehealth companies and pharmacies to prepare for increased peptide demand.
• Telehealth firms like Hims & Hers Health and pharmacies such as Olympia Pharmaceuticals have invested heavily in peptide manufacturing and protocols, anticipating a surge in peptide prescriptions similar to the GLP-1 medication boom.
• Some clinics, including Amanecia Health, have already begun prescribing peptides like BPC-157 despite limited safety and efficacy data, while industry groups caution pharmacies to comply with current laws to avoid legal issues.
• Peptides remain widely available on the gray market for research use only, with many new companies entering the space, intensifying competition despite legal and safety concerns highlighted by organizations like the Skin Cancer Foundation.